Anlotinib Recruiting Phase 2 Trials for Early Stage / Anlotinib / Peg-aspargase / Sintilimab / Open / Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type / Phase Two / Single Center Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03936452Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma
NCT04004572Sintilimab, Pegaspargase and Anlotinib for Stage IV Natural Killer /T-cell Lymphoma
NCT03618238Anlotinib for Advanced and Refractory Natural Killer /T-cell Lymphoma